Moteur de recherche d’entreprises européennes
Financement de l’UE (2 499 674 €) : La modulation allostérique des complexes de points de contrôle immunitaires comme nouveau mode d’intervention thérapeutique en immunothérapie Hor28/05/2024 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
La modulation allostérique des complexes de points de contrôle immunitaires comme nouveau mode d’intervention thérapeutique en immunothérapie
The fastidious balance of our immune system to fight infections or cancer while avoiding autoimmune reactions is regulated by coinhibitory and co-stimulatory immune checkpoint complexes (ICCs), which have become major drug targets. We witness the skyrocketing progression in cancer immunotherapy with antibodies that block inhibitory ICCs whereas Abs that block stimulatory ICCs are in clinical trials for treating autoimmune diseases. Surprisingly, but likely fuelled by the most obvious focus on IC inhibitors, the field largely ignored that ICCs are genuine transmembrane receptors that transmit signals upon binding of an extracellular protein ligand. This leaves unexplored modes of therapeutic intervention that I will uncover by validating Nanobodies (Nbs) as first-in-class modulators of signaling pathways associated with immune receptors in a unique, previously unexplored fashion. By applying innovative immunization and bio-selection techniques and building on POC data, I will deliver Nbs for representative ICCs to demonstrate the efficacy and selectivity of these Nbs in preclinical models of various inflammatory conditions, focusing on cancer and autoimmune diseases. We will deliver novel therapeutics agents which may outperform current inhibitor-based immunotherapies that trigger a magnitude of side effects. In this regard, the Nbs will exert their therapeutic effect through a distinctive mode of action that will ensure patient safety, even in the event of an overdose.
| VIB VZW | 2 499 674 € |
https://cordis.europa.eu/project/id/101141569
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel. L’état actuel est présenté à la page suivante : Vlaams Instituut Voor Biotechnologie - Flanders Institute for Biotechnology VZW, Gand, Belgique.
